Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03381586 · ClinicalTrials.gov registry record · Phase 1
QUILT-1.004: A Single Center, Open-label, Pharmacokinetic Study of Subcutaneous ALT-803
A Phase 1 study, sponsored by Altor BioScience.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT03381586: Completed Phase 1 study, sponsored by Altor BioScience.
NCT03381586 is a Phase 1 study that has completed, run by Altor BioScience. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03381586, a Phase 1 study, has completed, sponsored by Altor BioScience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a single center, open-label, pharmacokinetic study of ALT-803 administered as a subQ injection to healthy volunteers.
Primary Outcome
The period of time required for the concentration or amount of drug in the body to be reduced by one-half.
Interventions
- DRUG ALT-803
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-12-27 |
| Est. Completion | 2018-03-13 |
| Phase | Phase 1 |
What the finished NCT03381586 record still lists
NCT03381586 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 1 intervention - of which ALT-803 is the first listed.
NCT03381586 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03381586 about?
NCT03381586 is a clinical study titled "QUILT-1.004: A Single Center, Open-label, Pharmacokinetic Study of Subcutaneous ALT-803". This is a single center, open-label, pharmacokinetic study of ALT-803 administered as a subQ injection to healthy volunteers.
What is the current status of trial NCT03381586?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2017-12-27. Estimated completion is 2018-03-13.
What interventions are being tested in trial NCT03381586?
The interventions under investigation include: ALT-803 (DRUG).
Who is sponsoring clinical trial NCT03381586?
This trial is sponsored by Altor BioScience, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03381586's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI